Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Thomas Powles, Daniel M. Geynisman et al.|The Lancet Oncology|2021Cited by 411
The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in CancerYi Shi, Jianzhong Shen|Frontiers in Pharmacology|2020Cited by 339
Diagnosis and treatment of community‐acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical AssociationBin Cao, Jieming Qu, Yi Huang et al.|The Clinical Respiratory Journal|2017Cited by 321
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial CarcinomaThomas Powles, Sanjeev Mariathasan, Zoe J. Assaf et al.|European Urology|2023Cited by 128
Pyrroline‑5‑carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non‑small cell lung cancerFeng Cai, Yi Shi|Oncology Letters|2017Cited by 84